Literature DB >> 1647388

Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis.

R J Chiodini1.   

Abstract

The inhibitory and bactericidal, synergistic, and antagonistic activities of rifabutin combined with ciprofloxacin, ethambutol, clofazimine, cefazolin, and amikacin in dual and triple combinations against various human and animal isolates of Mycobacterium paratuberculosis were determined. Synergism was observed when rifabutin was combined with either cefazolin or clofazimine in double combinations. The greatest amount of synergy occurred with the rifabutin-cefazolin combination in which bactericidal synergism was present with all strains. Of the triple combinations examined, only rifabutin in combination with ethambutol and cefazolin or streptomycin and cefazolin showed bactericidal synergism against most of the strains. Although antagonism was not observed in any double combination with rifabutin, antagonism was shown with several of the triple combinations. The rifabutin-cefazolin and rifabutin-streptomycin-cefazolin combinations were found to have the greatest bactericidal synergism at concentrations well within achievable serum and tissue levels and may be appropriate choices for chemotherapeutic use.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647388     DOI: 10.1093/jac/27.2.171

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

Review 1.  Paratuberculosis.

Authors:  C Cocito; P Gilot; M Coene; M de Kesel; P Poupart; P Vannuffel
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

2.  How Long Does Antimycobacterial Antibiotic-loaded Bone Cement Have In Vitro Activity for Musculoskeletal Tuberculosis?

Authors:  Jae Hoo Lee; Chang Dong Han; Sang-Nae Cho; Ick Hwan Yang; Woo Suk Lee; Seung-Hun Baek; Jae Won Shin; Khalid Elfadil Ibrahim Husein; Kwan Kyu Park
Journal:  Clin Orthop Relat Res       Date:  2017-08-09       Impact factor: 4.176

3.  Use of rifabutin in treatment of systemic Mycobacterium paratuberculosis infection in mice.

Authors:  R J Chiodini; J M Kreeger; W R Thayer
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

4.  Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.

Authors:  Beatriz E Ferro; Joseph Meletiadis; Melanie Wattenberg; Arjan de Jong; Dick van Soolingen; Johan W Mouton; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 5.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.